SLC1A2 and Parkinson disease: Suppression of miR-543-3p can alleviate dyskinesia and restore GLT-1 expression and function in the PD model, which raises the possibility that miR-543-3p inhibition could be used as a possible therapeutic target for PD (Wu X. et al., 2019).